Monitor progress on NDA resubmission for GTx-104, as the dual-source manufacturing strategy and FDA reinspection timing are the key catalysts. The company's cash runway through end of 2028 provides a long operational runway, but no revenue is expected until potential FDA approval.
GRCE drugs
GRCE drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK AT ENTRY AT T+1- T+0 · Nov 12 $1.81entry
- T+1 · 4d ago 0.00%α +0.36% · $1.81
- T+2 · todayOpen
- T+5 · in 2d Pending
- T+20 · in 24d Pending
- T+60 · in 3mo Pending
Price Chart
How similar events traded
Executive Summary
Grace Therapeutics reported a Q2 2027 net loss of $2.1 million ($0.11 per share), wider than the $0.9 million loss in the prior-year quarter, driven by the expiration of warrant-related gains and higher R&D spending on its dual-source manufacturing strategy for GTx-104. Cash runway extends through end of calendar 2028, and the company continues to address FDA CMC items from the April 2026 Complete Response Letter with no new clinical data required.
Key Financial Metrics
Key Facts
- Net loss of $2.1 million ($0.11 per share) for three months ended September 30, 2026, vs. $0.9 million ($0.06 per share) a year ago
- Cash and cash equivalents of $21.3 million as of September 30, 2026, up from $17.0 million at March 31, 2026
- Completed $10 million private placement in August 2026, net proceeds of $9.2 million
- Cash used in operations for six months ended September 30, 2026 was approximately $5.0 million
- Company believes cash sufficient through end of calendar 2028
- Dual-source manufacturing strategy for GTx-104 progressing; NDA resubmission timing depends on whichever manufacturing site reaches readiness first
- No clinical safety or efficacy deficiencies identified in FDA Complete Response Letter
Financial Impact
Net loss increased by $1.2 million year-over-year; cash increased by $4.3 million from March 31, 2026 due to $9.2M private placement net proceeds
Risk Factors
- NDA resubmission timing uncertain, dependent on CMO remediation and FDA scheduling
- No approved products or revenue; pre-revenue biotech with binary regulatory outcome
- Potential need for additional capital if NDA resubmission is delayed or requires more resources
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001140361-26-043308 |
| Document: ef20085030_8k.htm | 0001140361-26-043308 |
| Document: 0001140361-26-043308-index-headers.html | 0001140361-26-043308 |
| Document: 0001140361-26-043308-index.html | 0001140361-26-043308 |
| Document: 0001140361-26-043308.txt | 0001140361-26-043308 |
| 8-K Data (Synthetic) | 0001140361-26-043308 |
Track record
15 reports on GRCE
4 of 5 bullish or bearish reports moved the stock their way by T+1. Best: +10.64% at T+5 after the Apr 23, 2026 report. 4 of 5 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $1.75 Now $1.75 0.00% settles Nov 18
- Nov 13, 20263d ago SC 13G/A Neutral 3/10 Entry $1.82 Now $1.75 −3.85% settles Nov 17
- Nov 12, 20264d ago 8-K Neutral 4/10 Viewing Entry $1.81 to $1.81 Now $1.75 −3.31% · 0.00% +0.36% vs SPY
- Sep 10, 20269w ago Insider Cluster Bullish 6/10 Entry $2.26 to $2.22 Now $1.75 −22.57% ▼ −1.77% −2.62% vs SPY
- Aug 13, 202613w ago 8-K Neutral 5/10 No price data
- Aug 13, 202613w ago Press Release Mixed 5/10 Entry $2.07 to $2.16 Now $1.75 −15.46% ▲ +4.35% +4.55% vs SPY
- Aug 4, 202614w ago Press Release Neutral 5/10 Entry $2.14 to $2.12 Now $1.75 −18.22% ▼ −0.93% −0.77% vs SPY
- Jul 28, 202615w ago 8-K Neutral 5/10 Entry $2.25 to $2.08 Now $1.75 −22.22% ▼ −7.56% −6.02% vs SPY
- Jun 18, 202621w ago 8-K Mixed 5/10 Entry $2.38 to $2.26 Now $1.75 −26.47% ▼ −5.04% −4.73% vs SPY
- Jun 18, 202621w ago 8-K Bearish 6/10 No price data
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers